WO2021197401A8 - 结合cd47的抗原结合多肽及用途 - Google Patents

结合cd47的抗原结合多肽及用途 Download PDF

Info

Publication number
WO2021197401A8
WO2021197401A8 PCT/CN2021/084802 CN2021084802W WO2021197401A8 WO 2021197401 A8 WO2021197401 A8 WO 2021197401A8 CN 2021084802 W CN2021084802 W CN 2021084802W WO 2021197401 A8 WO2021197401 A8 WO 2021197401A8
Authority
WO
WIPO (PCT)
Prior art keywords
binding
antigen
polypeptide
tumor
binding polypeptide
Prior art date
Application number
PCT/CN2021/084802
Other languages
English (en)
French (fr)
Other versions
WO2021197401A1 (zh
Inventor
桂秋
朱虹
王亮亮
张晓云
邹筱芳
申恒巧
徐宏江
杨玲
Original Assignee
正大天晴药业集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 正大天晴药业集团股份有限公司 filed Critical 正大天晴药业集团股份有限公司
Priority to BR112022019795A priority Critical patent/BR112022019795A2/pt
Priority to CN202180017777.7A priority patent/CN115190887A/zh
Priority to CA3177519A priority patent/CA3177519A1/en
Priority to AU2021250200A priority patent/AU2021250200A1/en
Priority to IL296829A priority patent/IL296829A/en
Priority to EP21780305.5A priority patent/EP4130042A1/en
Priority to JP2022560185A priority patent/JP2023519620A/ja
Priority to KR1020227037553A priority patent/KR20220163991A/ko
Publication of WO2021197401A1 publication Critical patent/WO2021197401A1/zh
Publication of WO2021197401A8 publication Critical patent/WO2021197401A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供一种结合CD47的抗原结合多肽或其抗原结合部分，以及编码多肽的核酸、载体、细胞、药物组合物，该多肽可减少肿瘤或抑制肿瘤细胞生长、治疗癌症、促进巨噬细胞吞噬作用等。
PCT/CN2021/084802 2020-04-02 2021-04-01 结合cd47的抗原结合多肽及用途 WO2021197401A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR112022019795A BR112022019795A2 (pt) 2020-04-02 2021-04-01 Polipeptídeo de ligação a antígeno que se liga a cd47 e uso deste
CN202180017777.7A CN115190887A (zh) 2020-04-02 2021-04-01 结合cd47的抗原结合多肽及用途
CA3177519A CA3177519A1 (en) 2020-04-02 2021-04-01 Antigen-binding polypeptide binding to cd47, and use thereof
AU2021250200A AU2021250200A1 (en) 2020-04-02 2021-04-01 Antigen-binding polypeptide binding to CD47, and use thereof
IL296829A IL296829A (en) 2020-04-02 2021-04-01 An antigen-binding polypeptide that binds to cd47 and its use
EP21780305.5A EP4130042A1 (en) 2020-04-02 2021-04-01 Antigen-binding polypeptide binding to cd47, and use thereof
JP2022560185A JP2023519620A (ja) 2020-04-02 2021-04-01 Ｃｄ４７に結合する抗原結合ポリペプチド及び用途
KR1020227037553A KR20220163991A (ko) 2020-04-02 2021-04-01 Cd47에 결합하는 항원-결합 폴리펩타이드 및 이의 용도

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010255615.4 2020-04-02
CN202010255615 2020-04-02

Publications (2)

Publication Number Publication Date
WO2021197401A1 WO2021197401A1 (zh) 2021-10-07
WO2021197401A8 true WO2021197401A8 (zh) 2021-11-04

Family

ID=77927419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/084802 WO2021197401A1 (zh) 2020-04-02 2021-04-01 结合cd47的抗原结合多肽及用途

Country Status (10)

Country Link
EP (1) EP4130042A1 (zh)
JP (1) JP2023519620A (zh)
KR (1) KR20220163991A (zh)
CN (1) CN115190887A (zh)
AU (1) AU2021250200A1 (zh)
BR (1) BR112022019795A2 (zh)
CA (1) CA3177519A1 (zh)
IL (1) IL296829A (zh)
TW (1) TW202144407A (zh)
WO (1) WO2021197401A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118076644A (zh) * 2021-09-30 2024-05-24 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体
CN118055947A (zh) * 2021-09-30 2024-05-17 正大天晴药业集团南京顺欣制药有限公司 联合治疗血液肿瘤的抗cd47抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP4349868A2 (en) 2010-05-14 2024-04-10 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
BR112015013431A2 (pt) * 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
JP6909153B2 (ja) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
TW201819413A (zh) * 2016-11-28 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EP3845561A4 (en) * 2018-08-31 2022-07-06 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-CD47 ANTIBODIES AND ITS USE
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途

Also Published As

Publication number Publication date
WO2021197401A1 (zh) 2021-10-07
EP4130042A1 (en) 2023-02-08
KR20220163991A (ko) 2022-12-12
CN115190887A (zh) 2022-10-14
TW202144407A (zh) 2021-12-01
IL296829A (en) 2022-11-01
AU2021250200A1 (en) 2022-12-01
BR112022019795A2 (pt) 2022-11-16
CA3177519A1 (en) 2021-10-07
JP2023519620A (ja) 2023-05-11

Similar Documents

Publication Publication Date Title
WO2021197401A8 (zh) 结合cd47的抗原结合多肽及用途
WO2020142659A3 (en) Multi-specific protein molecules and uses thereof
WO2020014285A3 (en) Fusion constructs and methods of using thereof
WO2016081748A3 (en) Antibodies against cd73 and uses thereof
NZ583282A (en) Human c-fms antigen binding proteins
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO1999014327A3 (en) Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
EP2583981A3 (en) Antibodies and related molecules that bind to PSCA proteins
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO1997003635A3 (en) P16 expression constructs and their application in cancer therapy
WO2001009189A3 (en) Compositions and methods for the treatment of tumors
WO2020154714A3 (en) Systems and methods for modulating crispr activity
WO2003066663A3 (en) Peptides for recognition and targeting of glial cell tumors
WO2021216876A3 (en) Antibodies to coronavirus spike protein and methods of use thereof
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2023159136A3 (en) Epitope engineering of cell-surface receptors
WO2003064614A3 (en) Transport peptides and uses therefor
WO2023168384A3 (en) Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2
WO2009017463A3 (en) NOVEL β-GLUCANS ISOLATED FROM HIGHER BASIDIOMYCETES MUSHROOM GANODERMA TSUGAE VAR. JANNIEAE
WO2018152446A3 (en) Cell-penetrating atf5 polypeptides and uses thereof
WO2023250384A3 (en) Crispr-cas effector polypeptides and methods of use thereof
WO2022212947A8 (en) Kras-specific cyclic peptides, compositions, and methods of using and making
WO2023019121A8 (en) Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023107674A3 (en) Stapled peptide-antibody conjugates (spacs) and uses thereof
WO2017078761A3 (en) Her-2-specific cyclized supr peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21780305

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3177519

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022560185

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022019795

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227037553

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021780305

Country of ref document: EP

Effective date: 20221102

ENP Entry into the national phase

Ref document number: 112022019795

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220930

ENP Entry into the national phase

Ref document number: 2021250200

Country of ref document: AU

Date of ref document: 20210401

Kind code of ref document: A